VFA
RPRX

Virtus Fund Advisers’s Repros Therapeutics Inc. RPRX Stock Holding History

Virtus Fund Advisers’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-1,970
Closed -$34K – 2852
2014
Q2 		$34K Buy
+1,970
New +$32.1K ﹤0.01% 2128

Other funds holding RPRX

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
DCM
Destrier Capital Management New York $144M AUM 7.28% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BIM
Bogle Investment Management Newton Lower Falls, Massachusetts $63M AUM 51.97% 1-Year Est. Return

Virtus Fund Advisers's RPRX Position: Q3 2014 in Review

Virtus Fund Advisers sold out of Repros Therapeutics Inc. (RPRX) in Q3 2014, closing a stake of 1,970 shares — an estimated $34K sold.

Virtus Fund Advisers first reported a position in RPRX in Q2 2014 and held it in 1 quarter. The position peaked at $34K in Q2 2014. 75 funds tracked by Wall St. Rank hold RPRX as of Q3 2014.

  • Virtus Fund Advisers reported no remaining Repros Therapeutics Inc. position as of Q3 2014 after selling out during the quarter.
  • Virtus Fund Advisers sold 1,970 Repros Therapeutics Inc. shares in Q3 2014, an estimated $34K.
  • Virtus Fund Advisers first reported a position in Repros Therapeutics Inc. in Q2 2014 and held it in 1 quarter.
  • Virtus Fund Advisers's Repros Therapeutics Inc. position peaked at $34K in Q2 2014.
  • 75 funds tracked by Wall St. Rank held Repros Therapeutics Inc. as of Q3 2014.

Based on Virtus Fund Advisers's 13F filing for Q3 2014, filed 31 Oct 2014.